NVO News and Press, Novo Nordisk A/S From 06/18/24

2024-06-18 12:54:18 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...

2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...

2024-06-18 11:16:16 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Ozempic drives more demand for small...

2024-06-17 14:50:10 ET More on FlexShares Trust - FlexShares Quality Dividend Defensive Index Fund: QDEF: FlexShares' Defensive Dividend ETF Fails To Stand Out QDEF: Great Name, But Holdings Don't Validate Seeking Alpha’s Quant Rating on FlexShares Trust - Fle...

2024-06-17 14:28:29 ET More on Utilities Select Sector SPDR ETF, Health Care Select Sector SPDR, etc. XLU: Utilities Are Attractive, Some More Than Others Not Impressed By Either Of The Stories That Have Been Powering XLU XLU: Join Billionaires Trading Short-Term Pai...

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

2024-06-17 09:53:00 ET Structure Therapeutics (NASDAQ: GPCR) and Novo Nordisk (NYSE: NVO) have one big thing in common: the desire to compete in the bustling market for obesity therapies. While the pre-revenue biotech is still a fledgling in the midst of its attempt to devel...

2024-06-17 09:13:40 ET Summary Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a market dominated by Novo Nordisk and Eli Lilly. ...

2024-06-16 12:33:31 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...

2024-06-15 11:19:01 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Eli Lilly and Company (LLY) Goldman Sac...